Business Wire

Maxion Wheels and Challenge4 Set New Guinness World Record for High-Altitude Drive in an All-electric Vehicle

23.5.2022 19:37:00 EEST | Business Wire | Press release

Share

Maxion Wheels, the world’s largest wheel manufacturer, and long-distance driver Rainer Zietlow and the Challenge4 team, successfully set a new Guinness World Record for driving to the highest altitude in the all-electric VW ID.4 GTX. Equipped with Maxion’s robust, lightweight and sustainable steel wheels, the team drove to the top of Bolivia’s Uturuncu volcano, 5,816 meters above sea level, breaking the previous record set in 2020 by approx. 45 meters of altitude.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005816/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New highest altitude by an electric vehicle Guinness World Record is set by Maxion Wheels and Challenge4 with the ascent of a VW ID.4 GTX riding on Maxion steel wheels to the top of Bolivia's Uturuncu volcano. (Photo: Business Wire)

Guinness World Records today presented Challenge4 with the official certificate during a press conference at the German Embassy in La Paz, Bolivia. “This world record underscores the performance capabilities of electric vehicles such as the VW ID.4 GTX," said Rainer Zietlow, Challenge4 Director. "On the difficult terrain we encountered getting to the top of the Uturuncu volcano, robust wheels were crucial for a safe journey. Maxion Wheels' lightweight, 18-inch steel wheels kept the vehicle on track ensuring maximum electric vehicle (EV) range and performance." With his world record drive, Zietlow also supports the local SOS Children's Village in La Paz.

Maxion Wheels actively supported the high-altitude challenge from the very beginning, underlining its commitment to sustainability and reducing CO2 emissions. As a leading wheel supplier for EV programs and new mobility fleets around the world, the Company offers many sustainable wheel options made with greener materials, less energy and more efficient designs and processes, supporting the automotive industry’s transition towards carbon neutral.

“Congratulations to Rainer and the Challenge4 team for setting a new Guinness World Record; Maxion Wheels is proud to be part of this record-breaking moment,” said Mark Gerardts, Vice President Global Sales and Marketing at Maxion Wheels. “Electric cars such as the VW ID.4 GTX are enabling a generation shift in vehicle design and sustainability, driving demand for greener wheel options. We believe low-carbon steel wheels can play an important role in the shift to zero-carbon mobility as the most cost-effective and environmentally friendly wheel option.”

For many mobility options, Maxion’s steel wheels are the preferred solution. With a comparable weight to aluminum, steel wheels are meeting vehicle manufacturers need for lighter components. And with six times lower CO2 production compared to conventional aluminum wheels, steel wheels offer additional significant sustainability benefits.

Learn more about the high-altitude Guinness World Record drive at vwid4-highaltitude.com.

ABOUT MAXION WHEELS

Maxion Wheels, a division of Iochpe-Maxion S.A., is the world’s largest steel and aluminum wheel supplier. Our low-carbon expertise and energy-efficient designs help cars, buses, trucks and trailers achieve real-world carbon footprint reductions. Maxion is proud of its diverse global teams and inclusive culture that powers every advance we make.

Maxion Wheels works with global vehicle manufacturers on wheels for personal mobility, transportation, agriculture, defence and off-highway applications. Our more than 10,000 employees operate out of 30 locations in 14 countries on five continents, including state-of-the-art technical centers in the Americas, Europe, and Asia. Together we produce more than 50 million wheels a year, making us the world’s largest producer and supplier of wheels. To learn more, please visit Maxion Wheels’ website at maxionwheels.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Adrienne Hattingen
Global Marketing and Communications Supervisor
Maxion Wheels
Mobile: +49 172 8602873
Email: adrienne.hattingen@maxionwheels.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye